Literature DB >> 15611807

Symptom resolution in patients with Mycoplasma pneumoniae pneumonia.

Thomas J Marrie1, Michael Beecroft, Zeljka Herman-Gnjidic, Melanie Poulin-Costello.   

Abstract

BACKGROUND: Mycoplasma pneumoniae generally causes pneumonia of mild to moderate severity in adults. However, little is known about the time course of the resolution of symptoms in this illness.
OBJECTIVES: To determine the time course of the resolution of symptoms in M pneumoniae pneumonia.
METHODS: The severity of fatigue, cough, dyspnea, sputum and pleuritic chest pain were self-scored and recorded daily for 14 days and on days 30 and 42. Each symptom was scored on a scale of 0 to 5. The sum of the five symptom scores had a range of 0 to 25 and was transformed into a value from zero to 100 by multiplying by four.
RESULTS: The mean composite symptom score for 76 patients was 59 (out of 100) at presentation, which declined to a score of 17 on day 14. Patients with a score of greater than 20 on day 14 had significantly higher scores throughout the course of the illness. Thirty-four per cent of those who were employed did not take time off work.
CONCLUSIONS: Most patients with M pneumoniae pneumonia had resolution of their symptoms within two weeks; however, 12.6% were still symptomatic at 42 days.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15611807     DOI: 10.1155/2004/659187

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  2 in total

Review 1.  Gender analysis of moxifloxacin clinical trials.

Authors:  Elisa Chilet-Rosell; Ma Teresa Ruiz-Cantero; Ma Angeles Pardo
Journal:  J Womens Health (Larchmt)       Date:  2013-11-01       Impact factor: 2.681

2.  miR‑146a‑5p suppresses ATP‑binding cassette subfamily G member 1 dysregulation in patients with refractory Mycoplasma pneumoniae via interleukin 1 receptor‑associated kinase 1 downregulation.

Authors:  Hu-Nian Li; Xu Zhao; Yong-Jiu Zha; Fang Du; Jie Liu; Liang Sun
Journal:  Int J Mol Med       Date:  2019-10-22       Impact factor: 4.101

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.